title: Peroxisome proliferator-activated receptor gamma agonist rosiglitazone increases expression of very low density lipoprotein receptor gene in adipocytes.
abstract: Apolipoprotein E (apoE) and its receptor, very low density lipoprotein receptor (VLDLR), are involved in fat accumulation in adipocytes. Here, we investigated the effect of a peroxisome proliferator-activated receptor (PPAR) gamma agonist, rosiglitazone, on regulation of VLDLR expression both in white adipose tissue (WAT) of obese mice and in cultured adipocytes. Furthermore, to determine whether rosiglitazone directly regulates transcription of the VLDLR gene, we carried out luciferase assay with a reporter gene containing mouse VLDLR promoter region, electrophoretic mobility shift assay, and chromatin immunoprecipitation assay. Four-day treatment with rosiglitazone increased the expression of VLDLR in WAT of ob/ob mice. Moreover, rosiglitazone increased the expression of VLDLR in cultured adipocytes. The PPAR-responsive element (PPRE)-directed mutagenesis analyses revealed that the PPRE motif in the VLDLR promoter region plays a significant role in transcriptional activation of the VLDLR gene in adipocytes. In addition, electrophoretic mobility shift assay and chromatin immunoprecipitation assay demonstrated that endogenous PPARgamma directly binds to this functional PPRE motif in the VLDLR promoter region. We also investigated the effects of rosiglitazone on insulin sensitivity and lipid accumulation in both ob/ob mice and apoE-deficient ob/ob mice. Rosiglitazone ameliorated insulin sensitivity in both ob/ob mice and apoE-deficient ob/ob mice, possibly through decreasing the expression of monocyte chemoattractant protein-1 (MCP-1), increasing the expression of superoxide dismutase 1 (SOD1) in WAT, and increasing plasma adiponectin concentration. In ob/ob mice, body weight and WAT weight were significantly higher in the mice treated with rosiglitazone than those treated with vehicle. However, in apoE-deficient ob/ob mice, no significant difference in body weight or WAT weight was observed between the vehicle-treated group and the rosiglitazone-treated group. Moreover, rosiglitazone did not increase body weight and WAT weight in VLDLR-deficient mice. These findings indicate that rosiglitazone directly increases VLDLR expression, thereby enhancing apoE-VLDLR-dependent lipid accumulation in adipocytes.
authors.affiliation: Department of Metabolic Diseases, Graduate School of Medicine, 22nd Century Medical and Research Center, University of Tokyo, Tokyo, Japan.
authors.forename: Takeshi
authors.initials: T
authors.lastname: Takazawa
authors.forename: Toshimasa
authors.initials: T
authors.lastname: Yamauchi
authors.forename: Atsushi
authors.initials: A
authors.lastname: Tsuchida
authors.forename: Makoto
authors.initials: M
authors.lastname: Takata
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Hada
authors.forename: Masato
authors.initials: M
authors.lastname: Iwabu
authors.forename: Miki
authors.initials: M
authors.lastname: Okada-Iwabu
authors.forename: Kohjiro
authors.initials: K
authors.lastname: Ueki
authors.forename: Takashi
authors.initials: T
authors.lastname: Kadowaki
mesh_terms: D017667:Adipocytes / Q000378:metabolism*; D000818:Animals; D001057:Apolipoproteins E / Q000172:deficiency / Q000502:physiology; D001665:Binding Sites; D050356:Lipid Metabolism; D008297:Male; D051379:Mice; D008820:Mice, Obese; D047495:PPAR gamma / Q000819:agonists* / Q000378:metabolism; D011401:Promoter Regions, Genetic; D011973:Receptors, LDL / Q000235:genetics* / Q000378:metabolism; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000494:pharmacology*; D014158:Transcription, Genetic; D015854:Up-Regulation / Q000187:drug effects* / Q000235:genetics
chemical_list: D001057:Apolipoproteins E; D047495:PPAR gamma; D011973:Receptors, LDL; D045162:Thiazolidinediones; C036053:VLDL receptor; D000077154:Rosiglitazone
references.citation: Cell. 1996 Nov 1;87(3):377-89
references.pmid: 8898192
references.citation: J Biol Chem. 1995 Jun 2;270(22):12953-6
references.pmid: 7768881
references.citation: Diabetologia. 1999 Sep;42(9):1033-49
references.pmid: 10447513
references.citation: Endocrinology. 1994 Aug;135(2):798-800
references.pmid: 8033830
references.citation: J Biol Chem. 1991 Jul 25;266(21):13936-40
references.pmid: 1713211
references.citation: J Biol Chem. 1994 Jan 21;269(3):2173-82
references.pmid: 8294473
references.citation: Cell. 1994 Dec 30;79(7):1147-56
references.pmid: 8001151
references.citation: Endocrinology. 2001 Mar;142(3):1269-77
references.pmid: 11181544
references.citation: J Clin Invest. 2001 Oct;108(7):1001-13
references.pmid: 11581301
references.citation: Proc Natl Acad Sci U S A. 1992 Oct 1;89(19):9252-6
references.pmid: 1384047
references.citation: J Clin Invest. 2000 Nov;106(10):1221-8
references.pmid: 11086023
references.citation: J Biol Chem. 2002 May 3;277(18):15703-11
references.pmid: 11867619
references.citation: J Clin Invest. 2003 Dec;112(12):1796-808
references.pmid: 14679176
references.citation: J Clin Invest. 2004 Dec;114(12):1752-61
references.pmid: 15599400
references.citation: Nature. 2000 May 25;405(6785):421-4
references.pmid: 10839530
references.citation: Arterioscler Thromb Vasc Biol. 2001 Sep;21(9):1488-93
references.pmid: 11557677
references.citation: Arterioscler Thromb Vasc Biol. 2003 Aug 1;23(8):1423-9
references.pmid: 12842848
references.citation: Biochem Biophys Res Commun. 2001 Aug 31;286(4):735-41
references.pmid: 11520059
references.citation: Nature. 2003 Jun 12;423(6941):762-9
references.pmid: 12802337
references.citation: Diabetes. 2001 Aug;50(8):1863-71
references.pmid: 11473050
references.citation: Cell. 1999 Oct 29;99(3):239-42
references.pmid: 10555139
references.citation: J Clin Invest. 1989 Jan;83(1):137-42
references.pmid: 2521341
references.citation: J Biol Chem. 1995 Jun 30;270(26):15747-54
references.pmid: 7797576
references.citation: J Clin Invest. 2003 Dec;112(12):1821-30
references.pmid: 14679177
references.citation: J Lipid Res. 2004 Aug;45(8):1475-81
references.pmid: 15145981
references.citation: Diabetes. 2005 Dec;54(12):3358-70
references.pmid: 16306350
references.citation: J Biol Chem. 2003 Jan 24;278(4):2461-8
references.pmid: 12431986
references.citation: J Clin Invest. 1998 Mar 15;101(6):1354-61
references.pmid: 9502777
references.citation: Diabetes. 2007 Jan;56(1):24-33
references.pmid: 17192461
references.citation: J Biol Chem. 2002 Jul 19;277(29):25863-6
references.pmid: 12032136
references.citation: J Biol Chem. 1991 Jun 5;266(16):10583-8
references.pmid: 1709937
references.citation: Biochem Biophys Res Commun. 2008 Apr 11;368(3):716-22
references.pmid: 18262491
references.citation: J Biol Chem. 2002 Mar 22;277(12):10037-43
references.pmid: 11790777
references.citation: J Biol Chem. 2001 Nov 2;276(44):41245-54
references.pmid: 11533050
references.citation: Endocrinology. 1994 Jul;135(1):387-94
references.pmid: 8013374
references.citation: Nat Med. 2001 Aug;7(8):941-6
references.pmid: 11479627
references.citation: Annu Rev Biochem. 1985;54:699-727
references.pmid: 3896129